Home 2014

Archives

FDA approves Mekinist in combination with Tafinlar for advanced melanoma

On Jan. 10, the U.S. Food and Drug Administration (FDA) announced it had approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients...

Fever-reducing drugs may help spread flu

According to a study in Proceedings of the Royal Society B, the widespread use of fever reducing medications may lead to more cases of,...

Study: Vitamin E may slow decline from Alzheimer disease

“Effect of Vitamin E and memantine on functional decline in Alzheimer disease,” a study published in JAMA, reports that 2,000 units of vitamin E,...

Managing atrioventricular blocks

Not all AV blocks are dangerous. Find out which ones are and how they’re managed.

Preventing complications in patients receiving opioids

Understand the terms opioid tolerant and opioid naïve so you can safely administer opioids and protect patients.

Study: Decreased sepsis mortality

A study published by Critical Care Medicine reports that in-hospital mortality rates for sepsis decreased from 47% between 1991 and 1995 to 29% between...

Prescription opioids: A growing epidemic of abuse

Many people who take prescription opioids underestimate the abuse potential.

A swift, decisive response to GI bleeding

Coffee-ground emesis tips off caregivers to acute upper GI bleeding.

Recall of MedStream Programmable Infusion Pump and Refill Kits

On Oct. 23, the U.S. Food and Drug Administration (FDA) noted that Codman & Shrutleff, Inc., has recalled its MedStream Programmable Pump and MedStream...

FDA approves Brintellix for major depression

On Sept. 30, the U.S. Food and Drug Administration (FDA) approved Brintellix (vortioxetine) to treat adults with major depressive disorder. Read more.

Recall of metoclopramide and ondansetron injections

On Oct. 2, the U.S. Food and Drug Administration (FDA) noted that Hospira has recalled one lot of metoclopramide injection and two lost of...

FDA approved Adempas for pulmonary hypertension

On Sept. 30, the U.S. Food and Drug Administration (FDA) approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Read more.

FDA approves Liposorber Apheresis System for pediatric use

On Oct. 10, the U.S. Food and Drug Administration (FDA) approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis (FSGS)...